| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Biomedicum Helsinki, Research Program for Developmental and Reproductive Biology, Helsinki, Finland
2 Biomedicum Helsinki, Research Program for Developmental and Reproductive Biology, Helsinki, Finland; Institute of Biomedicine, University of Helsinki, Helsinki, Finland
* To whom correspondence should be addressed. E-mail: nina.linder{at}hus.fi.
Xanthine oxidoreductase (XOR) catalyzes the final reactions of purine catabolism, and may account for cell damage by producing reactive oxygen metabolites in cells reoxygenated after hypoxia. We found a 3-8-fold higher XOR activity in cultured human bronchial epithelial cells exposed to hypoxia (0.5-3% O2) compared to cells grown in normoxia (21% O2), but no difference in XOR protein or mRNA. XOR promoter constructs failed to respond to hypoxia. The cellular XOR activity at 3% O2 returned to basal levels when the cells were returned to 21% O2, and hyperoxia (95% O2) abolished enzyme activity with no change in XOR protein. Our data suggest reversible enzyme inactivation by oxygen or its metabolites. NADH was normally oxidized by the oxygen-inactivated enzyme, which rules out damage to the FAD cofactor. Hydrogen peroxide partially inactivated the molybdenum center of XOR, as shown by a parallel decrease in XOR-catalyzed xanthine oxidation and dichlorophenolindophenol reduction. We conclude that the transcription or translation of XOR are not influenced by hypoxia or hyperoxia. Instead, the molybdenum center of XOR is post-translationally inactivated by oxygen metabolites in normal (21% O2) cell culture atmosphere. This inactivation is reversed in hypoxia and accounts for the apparent induction.
This article has been cited by other articles:
|
|
 |
|
  A. Boueiz, M. Damarla, and P. M. Hassoun Xanthine oxidoreductase in respiratory and cardiovascular disorders Am J Physiol Lung Cell Mol Physiol, May 1, 2008; 294(5): L830 - L840. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N Linder, C Haglund, M Lundin, S Nordling, A Ristimaki, A Kokkola, J Mrena, J-P Wiksten, and J Lundin Decreased xanthine oxidoreductase is a predictor of poor prognosis in early-stage gastric cancer. J. Clin. Pathol., September 1, 2006; 59(9): 965 - 971. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. E. Griguer, C. R. Oliva, E. E. Kelley, G. I. Giles, J. R. Lancaster Jr., and G. Y. Gillespie Xanthine Oxidase-Dependent Regulation of Hypoxia-Inducible Factor in Cancer Cells Cancer Res., February 15, 2006; 66(4): 2257 - 2263. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. M. Saraiva, K. M. Minhas, S. V.Y. Raju, L. A. Barouch, E. Pitz, K. H. Schuleri, K. Vandegaer, D. Li, and J. M. Hare Deficiency of Neuronal Nitric Oxide Synthase Increases Mortality and Cardiac Remodeling After Myocardial Infarction: Role of Nitroso-Redox Equilibrium Circulation, November 29, 2005; 112(22): 3415 - 3422. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Linder, J. Lundin, J. Isola, M. Lundin, K. O. Raivio, and H. Joensuu Down-Regulated Xanthine Oxidoreductase Is a Feature of Aggressive Breast Cancer Clin. Cancer Res., June 15, 2005; 11(12): 4372 - 4381. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. E. Conour, W. V. Graham, and H. R. Gaskins A combined in vitro/bioinformatic investigation of redox regulatory mechanisms governing cell cycle progression Physiol Genomics, July 8, 2004; 18(2): 196 - 205. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Visit Other APS Journals Online |
